STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBNX
  4. [Form 4] Beta Bionics, Inc. Insider Trading Activity

Beta Bionics (BBNX) CFO sells 10,000 shares under 10b5-1 trading plan

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an exercise-and-sell pattern in Common Stock. He exercised stock options covering 9,878 shares at an exercise price of $5.10 per share and sold 10,000 shares in open-market transactions at weighted average prices around $17.04 on June 26, 2026 and June 29, 2026. The sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2025. Following these transactions, he directly holds 165,931 shares of Common Stock, indicating he retained a large majority of his equity position.

Positive

  • None.

Negative

  • None.
Insider Feider Stephen
Role Chief Financial Officer
Sold 10,000 shs ($170K)
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) 4,896 $0.00 --
Exercise Common Stock 4,896 $5.10 $25K
Sale Common Stock 4,896 $17.0304 $83K
Exercise Employee Stock Option (right to buy) 4,982 $0.00 --
Exercise Common Stock 4,982 $5.10 $25K
Sale Common Stock 5,104 $17.0467 $87K
Holdings After Transaction: Employee Stock Option (right to buy) — 39,817 shares (Direct, null); Common Stock — 170,827 shares (Direct, null)
Footnotes (1)
  1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
Shares sold 10,000 shares Total Common Stock sold in open-market transactions
Weighted average sale price 6/26/2026 $17.046782/share Common Stock sales on June 26, 2026
Weighted average sale price 6/29/2026 $17.0304/share Common Stock sales on June 29, 2026
Options exercised 9,878 shares Employee stock options converted to Common Stock
Option exercise price $5.10/share Employee Stock Option (right to buy) exercise price
Shares owned after transactions 165,931 shares Direct Common Stock ownership following transactions
10b5-1 plan adoption date May 15, 2025 Plan governing pre-arranged sales
Option expiration September 13, 2033 Expiration date for the reported employee stock options
Rule 10b5-1 Plan regulatory
"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
weighted average sale price financial
"The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12."
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feider Stephen
(Last)(First)(Middle)
C/O BETA BIONICS, INC.
11 HUGHES
(Street)
IRVINE CALIFORNIA 92618
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/26/2026M4,982A$5.1171,035D
Common Stock06/26/2026S(1)5,104D$17.0467(2)165,931D
Common Stock06/29/2026M4,896A$5.1170,827D
Common Stock06/29/2026S(1)4,896D$17.0304(3)165,931D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$5.106/26/2026M4,982 (4)09/13/2033Common Stock4,982$044,713D
Employee Stock Option (right to buy)$5.106/29/2026M4,896 (4)09/13/2033Common Stock4,896$039,817D
Explanation of Responses:
1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
2. The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
4. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
/s/ Stephen Feider06/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Beta Bionics (BBNX) CFO Stephen Feider report in this Form 4?

He reported exercising stock options and selling shares of Beta Bionics Common Stock. The filing shows coordinated option exercises and open-market sales over two days, while retaining a substantial remaining direct share position after the transactions.

How many Beta Bionics (BBNX) shares did the CFO sell and at what prices?

Stephen Feider sold a total of 10,000 shares of Common Stock. Weighted average sale prices were about $17.0468 on June 26, 2026 and $17.0304 on June 29, 2026, with individual trades occurring within narrow price ranges around those levels.

What stock options did the Beta Bionics (BBNX) CFO exercise?

He exercised employee stock options for 9,878 shares of Common Stock. These options carried an exercise price of $5.10 per share and were part of a grant that vests in 48 equal monthly installments beginning September 14, 2023, according to the disclosure.

How many Beta Bionics (BBNX) shares does the CFO hold after these transactions?

After the reported trades, Stephen Feider directly owns 165,931 shares of Beta Bionics Common Stock. This figure reflects his remaining equity stake following the option exercises and open-market sales disclosed in the Form 4 filing.

Were the Beta Bionics (BBNX) CFO’s stock sales pre-planned?

Yes. The filing states that the shares sold were pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025. Such plans pre-schedule trades, indicating the timing of these sales was arranged in advance rather than decided spontaneously.

What is the significance of the weighted average sale prices disclosed for BBNX?

The filing provides weighted average prices and price ranges for the sales, such as $17.046782 between $17 and $17.12. This detail helps investors understand the execution levels, and the filer offers to provide full breakdowns upon request to the company or SEC staff.